Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 4
2018 1
2019 1
2020 3
2021 2
2022 4
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, Zhao H, Chen R, Zu C, Gu T, Xiao P, Hong R, Feng J, Fu S, Kong D, Xu H, Cui J, Huang S, Liang B, Yuan X, Cui Q, Guo H, Yu Y, Feng Y, Jin C, Ren J, Chang AH, Wang D, Huang H. Hu Y, et al. Among authors: jing r. N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812. N Engl J Med. 2024. PMID: 38657244
Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma.
Zhang Q, Zu C, Jing R, Feng Y, Zhang Y, Zhang M, Lv Y, Cui J, Zhou L, Meng Y, Wang L, Cen Z, Chang AH, Hu Y, Huang H. Zhang Q, et al. Among authors: jing r. Front Immunol. 2023 May 4;14:1125357. doi: 10.3389/fimmu.2023.1125357. eCollection 2023. Front Immunol. 2023. PMID: 37215107 Free PMC article.
Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT, Meng Y, Kong DL, Wei GQ, Zhang MM, Wu WJ, Shi JM, Luo Y, Zhao YM, Yu J, Jing RR, Zhao MY, Zhao HL, Huang H, Hu YX. Yang TT, et al. Front Immunol. 2022 Aug 30;13:934442. doi: 10.3389/fimmu.2022.934442. eCollection 2022. Front Immunol. 2022. PMID: 36110859 Free PMC article.
23 results